GSK Bubble Baby Syndrome Gene Therapy Gets NICE Nod
The cost of Strimvelis is €594,000 but treatment is usually given once only and thought to be life-long. It is administered at a hospital in Milan but travel will be also paid for by the NHS.
You may also be interested in...
Spark's Luxturna is all but guaranteed to reach the US market as the first gene therapy following a unanimous positive FDA advisory committee review. Discussions about cost and value are sure to intensify.
UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.
The POTENTE trial demonstrated Fasenra’s impact in eliminating or reducing oral corticosteroid use for severe asthma patients, which should help AstraZeneca as it takes on GlaxoSmithKline’s rival IL-5 inhibitor, Nucala.